REGENERON PHARMACEUTICALS INC. - COMMON STOCK

Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma

07 апр 2024 16:00:12 Источник Nasdaq GlobeNewswire

Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024

01 апр 2024 16:05:00 Источник Nasdaq GlobeNewswire

Regeneron Provides Update on Biologics License Application for Odronextamab

25 мар 2024 07:00:02 Источник Nasdaq GlobeNewswire

High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization

12 мар 2024 21:30:22 Источник Nasdaq GlobeNewswire

Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

11 мар 2024 07:00:23 Источник Nasdaq GlobeNewswire

EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet

08 мар 2024 07:00:26 Источник Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

28 фев 2024 09:48:56 Источник NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

26 фев 2024 09:48:37 Источник NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

23 фев 2024 09:45:04 Источник NetDania Notify

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation

23 фев 2024 01:00:00 Источник Nasdaq GlobeNewswire

Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

21 фев 2024 07:00:13 Источник Nasdaq GlobeNewswire

Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)

16 фев 2024 00:59:00 Источник Nasdaq GlobeNewswire

Regeneron Announces Investor Conference Presentations

06 фев 2024 16:05:00 Источник Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

02 фев 2024 09:45:10 Источник NetDania Notify

Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

02 фев 2024 06:30:01 Источник Nasdaq GlobeNewswire

Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma

02 фев 2024 06:00:04 Источник Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

31 янв 2024 09:45:04 Источник NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

30 янв 2024 09:50:53 Источник NetDania Notify

Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs

30 янв 2024 07:00:41 Источник Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

26 янв 2024 09:47:16 Источник NetDania Notify